Pharmaceutical Transparency and the Case for Independent Drug Testing
If you publish false stuff-
Yeah
... there should be some type of ramification
for it, especially when you can prove
it.
Yeah. So the way that they get around this,
if you look at the way that media
reports on, you know, drug company studies, is that there is a,
again, false perception that the regulators,
whether it be the FDA in the
US or the MHR in the UK, are actually independent
actors evaluating the data and saying, "Yeah,
this is good." So that's how they get
around it. But the reality is that's not the case. There is biases.
They take money from pharma. They don't, you know...
When peer reviewers are reviewing an article that's being
published in a medical
journal, and John Abramson from Harvard points this
out very well in his book,
Sickening: How Big Pharma Broke American Healthcare,
the peer reviews do not have
access to the raw data. So what they are reviewing is a curated version of what
drug companies have told them. So, you know, with one stroke of a pen,
potentially
from President Trump, you could essentially say from now on,
and this is, you know,
enough is enough, Steven. It's very clear over the years,
because of these lack of
transparency in the data, millions and millions of people have been killed
over the last few decades from big pharma manipulations.
Absolutely.
Quality, p- people's lives destroyed. Enough is enough, right?
One simple solution is from now on, drug companies can develop drugs,
but they should no longer be allowed to test them themselves.
End of transcript · 265 words